STOCK TITAN

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that CEO David Stamler will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum on January 8, 2022, during the J.P. Morgan Healthcare Conference. Dr. Stamler will join a panel titled 'New Approaches to Parkinson's and Movement Disorders,' provide a company update, and engage in investor meetings. The forum will address global bio-partnering advancements and scientific developments in neurodegenerative diseases, which includes key areas like neuropsychiatry and digital therapeutics.

Positive
  • None.
Negative
  • None.

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.

(PRNewsfoto/Alterity Therapeutics Limited)

At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders." He will also present a company update and participate in investor and business development meetings.

The program for the 6th Annual NIF is designed to cover the latest developments in global bio-partnering and investment, with additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes neuropsychiatry, ophthalmology, neurotech and digital therapeutics.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

 Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-the-sachs-associates-6th-annual-neuroscience-innovation-forum-301712033.html

SOURCE Alterity Therapeutics Limited

FAQ

What is Alterity Therapeutics participating in on January 8, 2022?

Alterity Therapeutics is participating in the Sachs Associates 6th Annual Neuroscience Innovation Forum.

Who will represent Alterity Therapeutics at the Neuroscience Innovation Forum?

CEO David Stamler will represent Alterity Therapeutics at the forum.

What topics will be discussed at the Neuroscience Innovation Forum?

The forum will cover new approaches to Parkinson's diseases and other neurodegenerative conditions.

What is the significance of the Sachs Associates Neuroscience Innovation Forum?

It showcases advancements in global bio-partnering and investment in neurodegenerative diseases.

What is Alterity's lead asset aimed at treating?

Alterity's lead asset, ATH434, is aimed at treating various Parkinsonian disorders.

Alterity Therapeutics Limited American Depositary Shares

NASDAQ:ATHE

ATHE Rankings

ATHE Latest News

ATHE Stock Data

18.36M
8.74M
1.28%
0.04%
Biotechnology
Healthcare
Link
United States of America
Melbourne